The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy

Bibliographic Details
Main Authors:	Bjorkander, J, Spickett, G, Ericson, D, Engl, W, Eibl, M, Chapel, H
Format:	Journal article
Published:	2000

Similar Items

Subcutaneous immunoglobulin replacement therapy: the European experience.
by: Chapel, H, et al.
Published: (2013)

Intravenous immunoglobulin therapy.
by: Chapel, H
Published: (1996)

Home intravenous immunoglobulin therapy.
by: Chapel, H, et al.
Published: (1988)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
by: Martin Adriana, et al.
Published: (2012-11-01)

Self-infusion programmes for immunoglobulin replacement at home: feasibility, safety and efficacy.
by: Bhole, M, et al.
Published: (2008)

Immunoglobulin replacement therapy for primary immunodeficiencies.
by: Peter, J, et al.
Published: (2014)

Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens
by: Chouksey Akhilesh, et al.
Published: (2005-09-01)

Immunoglobulin replacement therapy by self-infusion at home.
by: Chapel, H, et al.
Published: (1988)

The safety and efficacy of intravenous immunoglobulin in autoimmune encephalitis
by: Soon‐Tae Lee, et al.
Published: (2022-05-01)

Fatigue Is Common in Immunoglobulin G Subclass Deficiency and Correlates With Inflammatory Response and Need for Immunoglobulin Replacement Therapy
by: Per Wågström, et al.
Published: (2022-01-01)

Hepatitis C and intravenous immunoglobulin - Concluding remarks
by: Chapel, H
Published: (1996)

EFFICACY AND SAFETY OF CLADRIBINE: SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN HAIRY CELL LEUKEMIA PATIENTS
by: Ola Khorshid, et al.
Published: (2015-10-01)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
by: Suzanne Skoda-Smith, et al.
Published: (2009-12-01)

Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
by: Martin Adriana, et al.
Published: (2012-11-01)

Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita.
by: Tayal, U, et al.
Published: (2008)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
by: M. Dolenc-Voljč, et al.
Published: (2013-11-01)

OUTBREAK OF ACUTE HEPATITIS-C FOLLOWING INTRAVENOUS IMMUNOGLOBULIN THERAPY
by: Healey, C, et al.
Published: (1994)

Intravenous immunoglobulin and hepatitis C virus: the British episode.
by: Healey, C, et al.
Published: (1996)

Clinical and laboratory observation on immunoglobulin replacement therapy switching from an intravenous to a subcutaneous route in a Malaysian X-linked agammaglobulinemia patient
by: Ali, Adli, et al.
Published: (2022)

Efficacy and Safety Analysis of Combination Therapy Consisting of Intravenous Immunoglobulin and Corticosteroids versus Respective Monotherapies in the Treatment of Relapsed ITP in Adults
by: Lijun Fang, et al.
Published: (2023-06-01)

Hepatitis G virus in intravenous immunoglobulin - Reply
by: Healey, C, et al.
Published: (1996)

Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
by: Scheuerlein, P, et al.
Published: (2018)

Sentiment analysis of subcutaneous and intravenous immunoglobulin therapy: public healthcare perception through social media discourse
by: Alejandro Tarango-García, et al.
Published: (2024-10-01)

When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach
by: Jolles, S, et al.
Published: (2016)

Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
by: Monica A. Kaminski, et al.
Published: (2020-12-01)

Advantage of the subcutaneous immunoglobulin replacement therapy in primary immunodeficient patients with or without secondary protein loss
by: Pınar Gür-Çetinkaya, et al.
Published: (2018-06-01)

The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiency
by: Selime Özen Bölük, et al.
Published: (2023-06-01)

Intravenous Immunoglobulin Therapy in Myocarditis
by: Amir Hossein Mansourabadi, et al.
Published: (2020-08-01)

One-year intravenous immunoglobulin replacement therapy: efficacy in reducing hospital admissions in pediatric patients with Inborn Errors of Immunity
by: Karina Mescouto de Melo, et al.
Published: (2022-03-01)

Assessment of local adverse reactions to subcutaneous immunoglobulin (SCIG) in clinical trials
by: Ballow, M, et al.
Published: (2017)

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency
by: Ducruet Thierry, et al.
Published: (2011-11-01)

European surveillance of immunoglobulin safety--results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries.
by: Quinti, I, et al.
Published: (2002)

Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
by: Mona Al-Ahmad, et al.
Published: (2017-01-01)

Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study
by: Bruce Ritchie, et al.
Published: (2022-11-01)

Comparative study between the efficacy of Intravenous Immunoglobulin alone versus the efficacy of Intravenous Immunoglobulin combined with Steroids in treatment of Acute Myocarditis in Pediatric patients in Qena University Hospital
by: Alaa Abd El-sabour Bashier, et al.
Published: (2024-01-01)

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
by: Philippe Moreau, et al.
Published: (2008-12-01)

Efficacy of add‐on therapy with intravenous immunoglobulin in steroid hyporesponsive DRESS syndrome
by: Da Woon Sim, et al.
Published: (2022-03-01)

Guidelines: Prescribing intravenous immunoglobulin: Summary of Department of Health guidelines
by: Provan, D, et al.
Published: (2008)

Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction
by: Robert D. M. Hadden, et al.
Published: (2015-01-01)

Comparison of the Efficacy of Intravenous, Subcutaneous, and Suppository Morphine in Reducing Post Hysterectomy Pain
by: Sheida Shabanian, et al.
Published: (2020-12-01)